|
1
|
Li Z, Hu J, Chen P and Zeng Z: Incidence,
treatment, and survival analysis in esophageal neuroendocrine
carcinoma population. Transl Cancer Res. 9:4317–4329. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wong AT, Shao M, Rineer J, Osborn V,
Schwartz D and Schreiber D: Treatment and survival outcomes of
small cell carcinoma of the esophagus: An analysis of the National
Cancer Data Base. Dis Esophagus. 30:1–5. 2017.
|
|
3
|
Ji A, Jin R, Zhang R and Li H: Primary
small cell carcinoma of the esophagus: Progression in the last
decade. Ann Transl Med. 8:5022020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu L, Li Y, Liu X, Sun H, Zhang R, Zhang
J, Zheng Y, Wang Z, Liu S and Chen X: Treatment strategies and
prognostic factors of Limited-stage primary small cell carcinoma of
the esophagus. J Thorac Oncol. 12:1834–1844. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roskoski R: Targeting oncogenic Raf
protein-serine/threonine kinases in human cancers. Pharmacol Res.
135:239–258. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roskoski R: RAF protein-serine/threonine
kinases: Structure and regulation. Biochem Biophys Res Commun.
399:313–317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beeram M, Patnaik A and Rowinsky EK: Raf:
A strategic target for therapeutic development against cancer. J
Clin Oncol. 23:6771–6790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fazio N, Abdel-Rahman O, Spada F, Galdy S,
De Dosso S, Capdevila J and Scarpa A: RAF signaling in
neuroendocrine neoplasms: From bench to bedside. Cancer Treat Rev.
40:974–979. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dizdar L, Werner TA, Drusenheimer JC,
Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W,
Esposito I, et al: BRAFV600E mutation: A promising target in
colorectal neuroendocrine carcinoma. Int J Cancer. 144:1379–1390.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Idrees K, Padmanabhan C, Liu E, Guo Y,
Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD and Shi C: Frequent
BRAF mutations suggest a novel oncogenic driver in colonic
neuroendocrine carcinoma. J Surg Oncol. 117:284–289. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Capdevila J, Arqués O, Hernández Mora JR,
Matito J, Caratù G, Mancuso FM, Landolfi S, Barriuso J,
Jimenez-Fonseca P, Lopez Lopez C, et al: Epigenetic EGFR gene
repression confers sensitivity to therapeutic BRAFV600E blockade in
colon neuroendocrine carcinomas. Clin Cancer Res. 26:902–909. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pedoeem A, Azoulay-Alfaguter I, Strazza M,
Silverman GJ and Mor A: Programmed death-1 pathway in cancer and
autoimmunity. Clin Immunol. 153:145–152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen X, Xu X, Wang D, Liu J, Sun J, Lu M,
Wang R, Hui B, Li X, Zhou C, et al: Neoadjuvant sintilimab and
chemotherapy in patients with potentially resectable esophageal
squamous cell carcinoma (KEEP-G 03): An Open-label, single-arm,
phase 2 trial. J Immunother Cancer. 11:e0058302023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H,
Zhu L, Shen Y, Zhang H, Sun Y, et al: Original research:
Multicenter, single-arm, phase II trial of camrelizumab and
chemotherapy as neoadjuvant treatment for locally advanced
esophageal squamous cell carcinoma. J Immunother Cancer.
10:e0042912022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan X, Duan H, Ni Y, Zhou Y, Wang X, Qi H,
Gong L, Liu H, Tian F, Lu Q, et al: Tislelizumab combined with
chemotherapy as neoadjuvant therapy for surgically resectable
esophageal cancer: A prospective, single-arm, phase II study
(TD-NICE). Int J Surg. 103:1066802022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun JM, Shen L, Shah MA, Enzinger P,
Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al:
Pembrolizumab plus chemotherapy versus chemotherapy alone for
first-line treatment of advanced oesophageal cancer (KEYNOTE-590):
A randomised, placebo-controlled, phase 3 study. Lancet.
398:759–771. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab plus platinum-etoposide versus platinum-etoposide
in first-line treatment of extensive-stage small-cell lung cancer
(CASPIAN): A randomised, controlled, open-label, phase 3 trial.
Lancet. 394:1929–1939. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horn L, Mansfield AS, Szczęsna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
extensive-stage small-cell lung cancer. N Engl J Med.
379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen
G, Ji Y, Dvorkin M, Shi J, Pan Z, et al: Effect of First-line
serplulimab vs placebo added to chemotherapy on survival in
patients with Extensive-stage small cell lung cancer: The
ASTRUM-005 randomized clinical trial. JAMA. 328:1223–1232. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tian J, Chen JH, Chao SX, Pelka K,
Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J,
et al: Combined PD-1, BRAF and MEK inhibition in BRAFV600E
colorectal cancer: A phase 2 trial. Nat Med. 29:458–466. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board, : The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guleria P, Kumar S, Malik PS and Jain D:
PD-L1 expression in small cell and large cell neuroendocrine
carcinomas of lung: An immunohistochemical study with review of
literature. Pathol Oncol Res. 26:2363–2370. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lantuejoul S, Sound-Tsao M, Cooper WA,
Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi
N, et al: PD-L1 testing for lung cancer in 2019: Perspective from
the IASLC pathology committee. J Thorac Oncol. 15:499–519. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li R, Yang Z, Shao F, Cheng H, Wen Y, Sun
S, Guo W, Li Z, Zhang F, Xue L, et al: Multi-omics profiling of
primary small cell carcinoma of the esophagus reveals RB1
disruption and additional molecular subtypes. Nat Commun.
12:37852021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ooki A, Osumi H, Fukuda K and Yamaguchi K:
Potent molecular-targeted therapies for gastro-entero-pancreatic
neuroendocrine carcinoma. Cancer Metastasis Rev. 42:1021–1054.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishii H, Azuma K, Kawahara A, Yamada K,
Imamura Y, Tokito T, Kinoshita T, Kage M and Hoshino T:
Significance of programmed cell Death-ligand 1 expression and its
association with survival in patients with small cell lung cancer.
J Thorac Oncol. 10:426–430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamashita S, Abe H, Yamashita H, Yagi K,
Seto Y and Ushiku T: PD-L1 and HLA-class I expression status and
their therapeutic implication in oesophageal small-cell carcinoma.
Histopathology. 83:264–275. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang Z, Jin Y, Cai X, Chen L, Shen X, Li
B, Chen H and Li Y: Association of the programmed death ligand-1
combined positive score in tumors and clinicopathological features
in esophageal cancer. Thorac Cancer. 13:523–532. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xing J, Ying H, Li J, Gao Y, Sun Z, Li J,
Bai C, Cheng Y and Wu H: Immune checkpoint markers in
neuroendocrine carcinoma of the digestive system. Front Oncol.
10:1322020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ebert PJR, Cheung J, Yang Y, McNamara E,
Hong R, Moskalenko M, Gould SE, Maecker H, Irving BA, Kim JM, et
al: MAP kinase inhibition promotes T cell and anti-tumor activity
in combination with PD-L1 checkpoint blockade. Immunity.
44:609–621. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu L, Mayes PA, Eastman S, Shi H,
Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson
C, et al: The BRAF and MEK inhibitors dabrafenib and trametinib:
Effects on immune function and in combination with immunomodulatory
antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res.
21:1639–1651. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang L, Yu B, Liu Z, Wei J, Pan J, Jiang
C and Li Z: Analysis of the clinicopathological characteristics,
prognosis, and lymphocyte infiltration of esophageal neuroendocrine
neoplasms: A Surgery-based cohort and Propensity-score matching
study. Cancers (Basel). 15:17322023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Giannetta E, Guarnotta V, Rota F, de Cicco
F, Grillo F, Colao A and Faggiano A; NIKE: A rare rarity:
Neuroendocrine tumor of the esophagus. Crit Rev Oncol Hematol.
137:92–107. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen C, Hu H, Zheng Z, Yang Y, Chen W,
Qiao X, Li P and Zhang S: Clinical characteristics, prognostic
factors, and survival trends in esophageal neuroendocrine
carcinomas: A population-based study. Cancer Med. 11:4935–4945.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gu YM, Yang YS, Shi GD, Yan CY, Shang QX,
Zhang HL, Wang WP, Yuan Y and Chen LQ: Limited-stage small cell
carcinoma of the esophagus treated with curative esophagectomy: A
multicenter retrospective cohort study. J Surg Oncol.
126:1396–1402. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lu X, Luo J, Ling Y, Kong YZ, Feng LL,
Zhou J and Wang F: Management of small cell carcinoma of esophagus
in China. J Gastrointest Surg. 17:1181–1187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zou B, Li T, Zhou Q, Ma D, Chen Y, Huang
M, Peng F, Xu Y, Zhu J, Ding Z, et al: Adjuvant therapeutic
modalities in primary small cell carcinoma of esophagus patients: A
retrospective cohort study of multicenter clinical outcomes.
Medicine (Baltimore). 95:e35072016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Erdem S, Troxler E, Warschkow R, Tsai C,
Yerokun B, Schmied B, Stettler C, Blazer DG III, Hartwig M, Worni M
and Gloor B: Is There a role for surgery in patients with
neuroendocrine tumors of the esophagus? A Contemporary View from
the NCDB. Ann Surg Oncol. 27:671–680. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deng HY, Ni PZ, Wang YC, Wang WP and Chen
LQ: Neuroendocrine carcinoma of the esophagus: Clinical
characteristics and prognostic evaluation of 49 cases with surgical
resection. J Thorac Dis. 8:1250–1256. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou Y, Hou P, Zha KJ, Wang F, Zhou K, He
W and Gao JB: Prognostic value of pretreatment contrast-enhanced
computed tomography in esophageal neuroendocrine carcinoma: A
multi-center follow-up study. World J Gastroenterol. 26:4680–4693.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu S, Ge X, Gao Z, Zhou Q, Shi Y, Jiang
W, Yang M and Sun X: Clinicopathological analysis of 67 cases of
esophageal neuroendocrine carcinoma and the effect of postoperative
adjuvant therapy on prognosis. Medicine (Baltimore).
100:e273022021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Meng MB, Zaorsky NG, Jiang C, Tian LJ,
Wang HH, Liu CL, Wang J, Tao Z, Sun Y, Wang J, et al: Radiotherapy
and chemotherapy are associated with improved outcomes over surgery
and chemotherapy in the management of limited-stage small cell
esophageal carcinoma. Radiother Oncol. 106:317–322. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu J, Wang Y, Sun H, Zhang Y, Zhang W,
Shen W, Yang N, Tan B, Su X, Li L, et al: Surgery versus
radiotherapy for limited-stage small cell esophageal carcinoma: A
multicenter, retrospective, cohort study in China (ChiSCEC). Int J
Surg. 110:956–964. 2024. View Article : Google Scholar : PubMed/NCBI
|
